Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of COCs on Migraine
NCT06509503Phase 4Recruiting
- Sponsor
- Kafrelsheikh University
- Start
- Jul 2024
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in migraine (2 arms), sponsored by Kafrelsheikh University. Primary endpoint: Percentage of patients with ≥ 50% reduction in monthly headache days at 90 days. Started Jul 2024; status: recruiting.
02
Conditions
migraine
Beyond the preview
Go deeper on NCT06509503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509503.